Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 134

1.

Mode of action, in vitro activity, and in vivo efficacy of AFN-1252, a selective antistaphylococcal FabI inhibitor.

Kaplan N, Albert M, Awrey D, Bardouniotis E, Berman J, Clarke T, Dorsey M, Hafkin B, Ramnauth J, Romanov V, Schmid MB, Thalakada R, Yethon J, Pauls HW.

Antimicrob Agents Chemother. 2012 Nov;56(11):5865-74. doi: 10.1128/AAC.01411-12. Epub 2012 Sep 4.

2.

AFN-1252, a FabI inhibitor, demonstrates a Staphylococcus-specific spectrum of activity.

Karlowsky JA, Kaplan N, Hafkin B, Hoban DJ, Zhanel GG.

Antimicrob Agents Chemother. 2009 Aug;53(8):3544-8. doi: 10.1128/AAC.00400-09. Epub 2009 Jun 1.

3.

Resistance to AFN-1252 arises from missense mutations in Staphylococcus aureus enoyl-acyl carrier protein reductase (FabI).

Yao J, Maxwell JB, Rock CO.

J Biol Chem. 2013 Dec 20;288(51):36261-71. doi: 10.1074/jbc.M113.512905. Epub 2013 Nov 4.

4.

Pharmacokinetics, pharmacodynamics and efficacy of novel FabI inhibitor AFN-1252 against MSSA and MRSA in the murine thigh infection model.

Banevicius MA, Kaplan N, Hafkin B, Nicolau DP.

J Chemother. 2013 Feb;25(1):26-31. doi: 10.1179/1973947812Y.0000000061.

5.

The MUT056399 inhibitor of FabI is a new antistaphylococcal compound.

Escaich S, Prouvensier L, Saccomani M, Durant L, Oxoby M, Gerusz V, Moreau F, Vongsouthi V, Maher K, Morrissey I, Soulama-Mouze C.

Antimicrob Agents Chemother. 2011 Oct;55(10):4692-7. doi: 10.1128/AAC.01248-10. Epub 2011 Aug 8.

6.

AFN-1252 is a potent inhibitor of enoyl-ACP reductase from Burkholderia pseudomallei--Crystal structure, mode of action, and biological activity.

Rao KN, Lakshminarasimhan A, Joseph S, Lekshmi SU, Lau MS, Takhi M, Sreenivas K, Nathan S, Yusof R, Abd Rahman N, Ramachandra M, Antony T, Subramanya H.

Protein Sci. 2015 May;24(5):832-40. doi: 10.1002/pro.2655. Epub 2015 Apr 2.

7.

Activity of AFN-1252, a novel FabI inhibitor, against Staphylococcus aureus in an in vitro pharmacodynamic model simulating human pharmacokinetics.

Tsuji BT, Harigaya Y, Lesse AJ, Forrest A, Ngo D.

J Chemother. 2013 Feb;25(1):32-5. doi: 10.1179/1973947812Y.0000000060.

8.

Perturbation of Staphylococcus aureus gene expression by the enoyl-acyl carrier protein reductase inhibitor AFN-1252.

Parsons JB, Kukula M, Jackson P, Pulse M, Simecka JW, Valtierra D, Weiss WJ, Kaplan N, Rock CO.

Antimicrob Agents Chemother. 2013 May;57(5):2182-90. doi: 10.1128/AAC.02307-12. Epub 2013 Mar 4.

9.

In vitro activity (MICs and rate of kill) of AFN-1252, a novel FabI inhibitor, in the presence of serum and in combination with other antibiotics.

Kaplan N, Awrey D, Bardouniotis E, Berman J, Yethon J, Pauls HW, Hafkin B.

J Chemother. 2013 Feb;25(1):18-25. doi: 10.1179/1973947812Y.0000000063.

10.

In vitro activity of API-1252, a novel FabI inhibitor, against clinical isolates of Staphylococcus aureus and Staphylococcus epidermidis.

Karlowsky JA, Laing NM, Baudry T, Kaplan N, Vaughan D, Hoban DJ, Zhanel GG.

Antimicrob Agents Chemother. 2007 Apr;51(4):1580-1. Epub 2007 Jan 12. No abstract available.

11.

CG400462, a new bacterial enoyl-acyl carrier protein reductase (FabI) inhibitor.

Park HS, Yoon YM, Jung SJ, Yun IN, Kim CM, Kim JM, Kwak JH.

Int J Antimicrob Agents. 2007 Nov;30(5):446-51. Epub 2007 Aug 27.

PMID:
17723291
12.

Antistaphylococcal activities of CG400549, a new bacterial enoyl-acyl carrier protein reductase (FabI) inhibitor.

Park HS, Yoon YM, Jung SJ, Kim CM, Kim JM, Kwak JH.

J Antimicrob Chemother. 2007 Sep;60(3):568-74. Epub 2007 Jul 2.

14.

Discovery of a novel and potent class of FabI-directed antibacterial agents.

Payne DJ, Miller WH, Berry V, Brosky J, Burgess WJ, Chen E, DeWolf Jr WE Jr, Fosberry AP, Greenwood R, Head MS, Heerding DA, Janson CA, Jaworski DD, Keller PM, Manley PJ, Moore TD, Newlander KA, Pearson S, Polizzi BJ, Qiu X, Rittenhouse SF, Slater-Radosti C, Salyers KL, Seefeld MA, Smyth MG, Takata DT, Uzinskas IN, Vaidya K, Wallis NG, Winram SB, Yuan CC, Huffman WF.

Antimicrob Agents Chemother. 2002 Oct;46(10):3118-24.

15.

Antistaphylococcal activity of WCK 771, a tricyclic fluoroquinolone, in animal infection models.

Patel MV, De Souza NJ, Gupte SV, Jafri MA, Bhagwat SS, Chugh Y, Khorakiwala HF, Jacobs MR, Appelbaum PC.

Antimicrob Agents Chemother. 2004 Dec;48(12):4754-61.

16.

Discovery of 4-Pyridone derivatives as specific inhibitors of enoyl-acyl carrier protein reductase (FabI) with antibacterial activity against Staphylococcus aureus.

Takahata S, Iida M, Yoshida T, Kumura K, Kitagawa H, Hoshiko S.

J Antibiot (Tokyo). 2007 Feb;60(2):123-8.

PMID:
17420562
17.

Discovery of aminopyridine-based inhibitors of bacterial enoyl-ACP reductase (FabI).

Miller WH, Seefeld MA, Newlander KA, Uzinskas IN, Burgess WJ, Heerding DA, Yuan CC, Head MS, Payne DJ, Rittenhouse SF, Moore TD, Pearson SC, Berry V, DeWolf WE Jr, Keller PM, Polizzi BJ, Qiu X, Janson CA, Huffman WF.

J Med Chem. 2002 Jul 18;45(15):3246-56.

PMID:
12109908
18.

Complestatin exerts antibacterial activity by the inhibition of fatty acid synthesis.

Kwon YJ, Kim HJ, Kim WG.

Biol Pharm Bull. 2015;38(5):715-21. doi: 10.1248/bpb.b14-00824.

19.

Type II fatty acid synthesis is essential for the replication of Chlamydia trachomatis.

Yao J, Abdelrahman YM, Robertson RM, Cox JV, Belland RJ, White SW, Rock CO.

J Biol Chem. 2014 Aug 8;289(32):22365-76. doi: 10.1074/jbc.M114.584185. Epub 2014 Jun 23.

20.

Meleagrin, a new FabI inhibitor from Penicillium chryosogenum with at least one additional mode of action.

Zheng CJ, Sohn MJ, Lee S, Kim WG.

PLoS One. 2013 Nov 28;8(11):e78922. doi: 10.1371/journal.pone.0078922. eCollection 2013.

Items per page

Supplemental Content

Write to the Help Desk